Avantor Investor Day Presentation Deck

1. RESEARCH & DEVELOPMENT Avantor's offering supports R&D activities Represents 55% of total Biopharma revenue¹ R&D PROCESS UNDERSTANDING MECHANISM OF DISEASE WORKFLOW SOLUTIONS Providing comprehensive solutions to enable scientists to achieve precise analytical results Navantor™ DRUG TARGET & IDENTIFICATION A Materials & consumables 1. Based on FY21 estimate, excluding pending M&A BIOPHARMACEUTICAL DEVELOPMENT Equipment & instrumentation TESTING IN BIOCHEMICAL & CELLULAR MODELS NY Services ANIMAL & FIRST IN MAN STUDIES 2,200 SERVICES ASSOCIATES 500+ CUSTOMERS 24

View entire presentation